|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Black brain : transformation of a melanocytoma with diffuse melanocytosis into a primary cerebral melanoma显示文摘 | Gempt J Buchmann N Grams AE | 2011 | J Neurooncol2011，102，2： | 1 |
| 2 | Black brain: transformation of a melanocytoma with diffuse melanocytosis into a primary cerebral melanoma 显示文摘 | Gempt J Buchmann N Grams AE | 2011 | J Neurooncol2011，102，： | 1 |
| 3 | Utility of diffusion tensor-imaged (DTI) motor fiber tracking for the resection of intracranial tumors near the corticospinal tract 显示文摘 | Buchmann N Gempt J Stoffel M | 2011 | Acta Neuro- chir (Wien)2011，153，1： | 1 |
| 4 | Endoscopic transnasal resection of the odontoid:case series and clinical course显示文摘 | Gempt J Lehmberg J Grams AE | | 0，，04： | 1 |
| 5 | Black brain:transformation of a melanocytoma with diffuse melanocytosis into a primary cerebral melanoma显示文摘 | Gempt J Buchmann N Grams AE | | 0，，02： | 1 |
| 6 | Safety and efficacy of a new percutaneously implantable interspinous process device显示文摘 | Kantelhardt SR Torok E Gempt J et aI | 2010 | Acta Neurochir(Wien)2010，152，11： | 1 |
| 7 | Frameless image-guided stereotaxy with real-time visual feedback for brain biopsy 显示文摘 | Gempt J Buchmann N Ryang YM | 2012 | Acta Neurochir (Wien)2012，154，： | 1 |
| 8 | Endoscopic transnasal resection of the odontoid:case series and clinical course显示文摘 | Gempt J Lehmberg J Grams AE | 2011 | Eur Spine J2011，20，4： | 1 |
| 9 | Black brain:transformation of a melanocytoma with diffuse melano-cytosis into a primary cerebral melanoma显示文摘 | Gempt J Buchmann N Grams AE | 2011 | J Neurooncol2011，102，2： | 1 |
| 10 | Neoadjuvant stereotactic radiosurgery for intracerebral metastases of solid tumors(NepoMUC):a phase I dose escalation trial显示文摘Background:More than 25%of patients with solid cancers develop intracerebral metastases.Aside of surgery,radia-tion therapy(RT)is a mainstay in the treatment of intracerebral metastases.Postoperative fractionated stereotactic RT(FSRT)to the resection cavity of intracerebral metastases is a treatment of choice to reduce the risk of local recur-rence.However,FSRT has to be delayed until a sufficient wound healing is attained;hence systemic therapy might be postponed.Neoadjuvant stereotactic radiosurgery(SRS)might offer advantages over adjuvant FSRT in terms of better target delineation and an earlier start of systemic chemotherapy.Here,we conducted a study to find the maximum tolerated dose(MTD)of neoadjuvant SRS for intracerebral metastases.Methods:This is a single-center,phase I dose escalation study on neoadjuvant SRS for intracerebral metastases that will be conducted at the Klinikum rechts der Isar Hospital,Technical University of Munich.The rule-based traditional 3+3 design for this trial with 3 dose levels and 4 different cohorts depending on lesion size will be applied.The primary endpoint is the MTD for which no dose-limiting toxicities(DLT)occur.The adverse events of each participant will be evaluated according to the Common Terminology Criteria for Adverse Events(CTCAE)version 5.0 continuously during the study until the first follow-up visit(4-6 weeks after surgery).Secondary endpoints include local control rate,survival,immunological tumor characteristics,quality of life(QoL),CTCAE grade of late clinical,neurological,and neurocognitive toxicities.In addition to the intracerebral metastasis which is treated with neoadjuvant SRS and resection up to four additional intracerebral metastases can be treated with definitive SRS.Depending on the occurrence of DLT up to 72 patients will be enrolled.The recruitment phase will last for 24 months.Discussion:Neoadjuvant SRS for intracerebral metastases offers potential advantages over postoperative SRS to the resection cavity,such as better target volume definition with subsequent higher efficiency of eliminating tumor cells,and lower damage to surrounding healthy tissue,and much-needed systemic chemotherapy could be initiated more rapidly. | Christian D.Diehl Ehab Shiban Christoph Straube Jens Gempt Jan J.Wilkens Markus Oechsner Carmen Kessel Claus Zimmer Benedict Wiestler Bernhard Meyer Stephanie E.Combs | 2019 | Cancer Communications2019，39，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员